Co-Diagnostics, CoSara plan Bundibugyo Ebola PCR assay program for global deployment

Co-Diagnostics, Inc.

Co-Diagnostics, Inc.

CODX

0.00
  • Co-Diagnostics set a joint development plan with CoSara to speed PCR assay readiness for Bundibugyo virus amid the Ebola outbreak.
  • Strategy targets international deployment if the outbreak expands, with CoSara positioned to support regional manufacturing and operations, subject to approvals.
  • Program will evaluate Bundibugyo-specific tests, pan-Ebola configurations, with workflows aimed at point-of-care, decentralized settings on its PCR platform.
  • WHO has classified the outbreak as a PHEIC, reporting more than 900 suspected cases, 220 suspected deaths.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Co-Diagnostics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202605260900PR_NEWS_USPR_____LA67526) on May 26, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.